Seroprevalence and risk factors of hepatitis B and C viruses among diabetes mellitus patients in Duhok province, Iraqi Kurdistan

Muayad A. Merza

1Department of Clinical Pharmacy, College of Pharmacy, University of Duhok, Duhok, Kurdistan Region, Iraq

ABSTRACT

Context: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major public health issues as they may progress into chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Aims: to identify the prevalence and risk factors of HBV and HCV among diabetic patients in Duhok province. Patients and Methods: It is a prospective study conducted in Shilan private hospital from June 2016 until December 2018. The serum of all diabetic patients was investigated by Enzyme-linked Immunosorbent Assay (ELISA) to detect HBsAg and anti-HCV. Diabetes mellitus (DM) was diagnosed according to American Diabetes Association (ADA). The results were analyzed by entering the data in Statistical Package for the Social Sciences (SPSS). Results: Three hundred seventy five DM patients were included in this study. The mean age of the patients was 54.38 ± 9.23, and the majority was female patients (65.87%). Out of 375 patients, 8 cases (2.13%) were HBV and 2 cases (0.53%) were HCV. Considering risk factors associated with HBV and HCV infections among diabetic patients, alcoholism was associated with both infections. Hemodialysis was a risk factor for HCV infection among diabetic patients but it was not associated with HBV. Conclusions: Although prevalence of HBV and HCV is higher among diabetic patients, its prevalence is low in comparison to other studies. It is recommended to screen HBsAg and anti-HCV in all alcoholic diabetic patients. Hemodialysis remains a significant risk factor for HCV transmission among diabetic patients with end stage renal disease (ESRD).

Keywords: Diabetes mellitus, HBV, HCV, risk factors, seroprevalence

Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major public health issues as they may progress into chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). HBV infects around one-third of the world population, with 257 million patients chronically infected.[1] On the other hand, chronic HCV infects approximately 1.0% of the world, which is estimated to be 71 million individuals.[2] In different parts of the world, hepatitis B and C viruses show great variation in their prevalence. In the Eastern Mediterranean Region the prevalence of HBV infection is 3.3%; whereas, the prevalence of HCV infection ranges from 1% to 2% excluding Egypt, where the prevalence rate is greater.[3,4] In Iraq, a prevalence rate of 1.6% and 0.4% for HBV and HCV was reported, respectively.[5]

Generally, viral infections can have a great role in the pathogenesis of Diabetes Mellitus (DM). The exact mechanism of HBV and HCV in the pathogenesis of DM is not well understood. Several studies found an association between insulin resistance and parenteral viral hepatitis, specially more prominent with HCV infection.[6] Patients with DM have a higher risk of acquiring hepatitis B and C viruses because they are more exposed
to medical interventions and are frequently hospitalized.\[^6\] Risk factors such as blood transfusions, dental interventions, hemodialysis, alcohol consumption, etc., are directly implicated to an increasing prevalence of HBV and HCV infections in diabetic patients.\[^7\]-\[^10\] Outbreaks of HBV infections were reported among DM patients who have had shared blood glucose devices. This could be linked to the low level of education regarding high risk of hepatitis B and C viruses’ transmission during finger stick testing.\[^11\],\[^12\]

Patients with DM are more prone to chronic liver diseases such as non-alcoholic steatohepatitis (NASH).\[^13\] Several studies have shown synergistic effects of parenteral viral hepatitis with DM in the advancement of chronic liver diseases.\[^13\],\[^14\] Although, this synergistic effect is very important, there is no data about the rate and risk factors of hepatitis B and C infections among diabetic patients in this region. Therefore, this study has aimed to identify the prevalence and risk factors of HBV and HCV among diabetic patients in Duhok province.

**Patients and Methods**

**Setting**

Shilan Hospital is a recognized private hospital, which provides medical and surgical services mainly for Duhok and neighboring cities. It has an additional attachment for consultation clinics of out-patients’ management such as clinics of infectious diseases, diabetes, pediatrics, gynecology, general surgery, etc.

**Study design and patients**

This is a prospective study that included all DM patients who accepted to participate in a blood test for hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus (anti-HCV) detection. All of included patients attending the clinic between June 2016 and December 2018 were interviewed. Type 2 DM patients were the only ones included. Exclusion criteria were as follows: type 1 and gestational DM, other causes of viral hepatitis e.g cytomegalovirus (CMV) infection and other types of hepatitis e.g. autoimmune hepatitis. The patients’ demographic profiles and certain risk factors related to HBV and HCV associated with DM were assessed.

**Laboratory investigations**

Blood samples were collected from the patients. Each sample consisting of 5 ml were obtained from the antecubital vein by a sterile disposable syringe. The blood was poured into a clean plain tube without anticoagulant and centrifuged at 3000 rpm for 5 minutes. The serum was investigated by Enzyme-linked Immunosorbent Assay (ELISA) to detect HBsAg and anti-HCV (Fortress Diagnostics Limited, Antrim, United Kingdom) according to the manufacturer instructions.\[^14\]

Furthermore, fasting plasma glucose and random glycaemia was performed using Cobas c 311/Cobas c 6000, and glycosylated hemoglobin (HbA1c) using Cobas c 311.

**Definitions**

HBV and HCV were defined based on the presence of HBsAg and anti-HCV in the serum of the patients, respectively. Diabetes mellitus was diagnosed according to American Diabetes Association (ADA).\[^16\]

**Statistical analysis**

The results obtained were analyzed by entering the data in Statistical Package for the Social Sciences (SPSS), version 16; SPSS Inc., Chicago, Illinois, USA. A P value ≤ 0.05 was considered statistically significant.

**Ethical approval**

This study was approved by the ethical committee of College of Pharmacy, University of Duhok. A written consent was obtained from all patients participating in this study.

**Results**

The demographic and clinical profile of the 375 documented DM patients is shown in Table 1. The mean age of the patients was 54.38 ± 9.23, and the majority was female patients (65.87%).

The prevalence of the infections among diabetic patients is shown in Table 2. There were 8 patients with HBV and 2 with HCV.

Considering risk factors associated with HBV and HCV infections among diabetic patients, alcoholism was associated with both infections. Hemodialysis was a risk factor for HCV infection among diabetic patients, but it was not associated with HBV. There were no other significant associations of variables between HBV and HCV among the study population [Table 3].

**Discussion**

To the best of my knowledge this is the first study aimed to identify prevalence and certain risk factors associated with HBV and HCV infections in Duhok, Kurdistan region.

The prevalence of HBV and HCV was 2.13, and 0.53, respectively, which is relatively higher than that of previous recorded studies among non-diabetic people in this region.\[^4\],\[^7\]-\[^10\] This can be justified by the numerous use of finger stick measurement of blood sugar and also due to frequent hospital admission of such patients. Furthermore, diabetic patients, particularly those with a long duration and poor glycemic control have a reduced immunity; hence they are more prone to develop chronic HBV infection. Worldwide, several studies generalized a higher prevalence rate of such viruses among diabetic patients.\[^20\]-\[^22\]

Considering seroprevalence of HCV, most literatures reported its prominence correlation with DM; hence, noting a higher prevalence of HCV among diabetic patients.\[^6\],\[^22\]-\[^29\] Contrarily, the seroprevalences of HBV among diabetics and non-diabetics is controversial in the existing literatures. A number of studies,
similar to this study, reported higher prevalence rates of HBV infection among diabetics, whereas, others did not find a variation. The prevalence of HBV in DM patients in this study was lower than those reported from Turkey (3.8%), China (13.5%), Nigeria, and Ghana (5.5%). Likewise, the prevalence of HCV in diabetic patients was also lower compared to studies from Turkey (3.3%), Iran (1.98%), China (6.8%), and Ethiopia (7.5%). Overall, the low prevalence rate of the infections, particularly HCV, among diabetics in this study is directly related to a low prevalence rate of these viruses in the general population of Duhok province.

In the current study, there were certain risk factors significantly associated with HBV and HCV infections in diabetic patients. Alcoholism was one of the predictors of these infections. In agreement, a study from Turkey found that the prevalence of both infections was higher among alcoholic cirrhotic patients.

Although many studies found a high prevalence of HCV among alcoholic patients, the same for HBV was not reported. As a matter of fact, several literatures documented a high prevalence of HCV infection among alcoholic people. This can be elucidated as a result of parenteral risk factors for the acquisition of HCV infection. On the contrary, few studies claimed that alcohol has a critical role in risky sexual behavior, which leads to acquiring sexually transmitted diseases (STD) such as HBV infection.

Synergistic effects between alcoholic DM patients with HBV and/or HCV, which progress into liver diseases are common. As a result of high prevalence of these infections among alcoholic diabetic patients in this study, it is strongly recommended to screen HBV and HCV in such vulnerable groups.

Although, in the current study, parenteral risk factors of HBV and HCV among DM patients were not associated with an increasing risk of such viruses, hemodialysis was an exception. Hemodialysis was a predictor of HCV in diabetic patients, but not HBV. In concordance to this finding, in 2017, a study was conducted in hemodialysis center of Duhok on 94 patients with end stage

### Table 1: Clinico-demographic profile of the patients (Total patients=375)

| Variable                  | No. | Percentage |
|---------------------------|-----|------------|
| Age year (mean±SD)        |     | 54.38±9.23 |
| Sex                       |     |            |
| Male                      | 128 | 34.13      |
| Female                    | 247 | 65.87      |
| Smoker                    |     |            |
| Yes                       | 54  | 14.40      |
| No                        | 321 | 85.60      |
| Alcoholic                 |     |            |
| Yes                       | 9   | 2.40       |
| No                        | 366 | 97.60      |
| Surgical intervention     |     |            |
| Yes                       | 237 | 63.20      |
| No                        | 138 | 36.80      |
| Dental intervention       |     |            |
| Yes                       | 209 | 69.07      |
| No                        | 96  | 30.93      |
| Blood transfusion         |     |            |
| Yes                       | 67  | 18.13      |
| No                        | 308 | 81.87      |
| Hemodialysis              |     |            |
| Yes                       | 9   | 2.40       |
| No                        | 366 | 97.60      |
| Immunosuppressive therapy |     |            |
| Yes                       | 13  | 3.47       |
| No                        | 362 | 96.53      |

### Table 2: Seroprevalence of hepatitis B and C infections among diabetes patients (total patients=375)

| Type of infection | Number | Percent |
|-------------------|--------|---------|
| HBV* (HBsAg positive) | 8      | 2.13    |
| HCV* (Anti-HCV positive) | 2      | 0.53    |

1-HBV: hepatitis B virus, 2-HCV: hepatitis C virus

### Table 3: Risk factors related to hepatitis B and C infections among diabetic patients

| Variable                  | Total | HBV status                  | HCV status                  | P  |
|---------------------------|-------|-----------------------------|-----------------------------|----|
|                           |       | Positive No (%) | Negative No (%) | Positive No (%) | Negative No (%) |    |
| Age                       | <40   | 31             | 1 (3.23)         | 30 (96.77)       | 0.502       | 1 (3.23) | 30 (96.77) | 0.159 |
|                           | ≥40   | 344            | 1 (2.93)         | 337 (97.07)      | 0.453       | 1 (0.29) | 343 (99.71) |
| Sex                       | Male  | 128            | 1 (0.8)          | 124 (99.2)       | 0.435       | 1 (0.78) | 127 (99.22) | 1.000 |
|                           | Female| 247            | 1 (0.41)         | 243 (99.6)       | 0.324       | 1 (0.40) | 246 (99.60) |
| Smoker                    | Yes   | 54             | 2 (3.70)         | 52 (96.30)       | 0.013       | 1 (11.11) | 8 (88.89) | 0.047 |
|                           | No    | 321            | 1 (0.31)         | 315 (99.7)       | 0.013       | 1 (11.11) | 8 (88.89) | 0.047 |
| Alcoholic                 | Yes   | 9              | 2 (22.22)        | 7 (77.78)        | 0.024       | 1 (3.23) | 30 (96.77) | 0.159 |
|                           | No    | 366            | 6 (1.64)         | 360 (98.36)      | 0.204       | 1 (0.27) | 365 (99.73) |
| Surgical procedures       | Yes   | 237            | 3 (1.27)         | 234 (98.73)      | 0.126       | 1 (0.42) | 236 (99.58) | 1.000 |
|                           | No    | 138            | 5 (3.62)         | 133 (96.38)      | 0.204       | 1 (0.27) | 137 (99.73) |
| Dental Procedures         | Yes   | 274            | 7 (2.58)         | 267 (97.52)      | 0.126       | 1 (0.36) | 273 (99.64) | 0.467 |
|                           | No    | 101            | 1 (0.99)         | 100 (99.01)      | 0.126       | 1 (0.99) | 100 (99.01) | 0.467 |
| Blood transfusion         | Yes   | 67             | 2 (2.99)         | 65 (97.01)       | 0.637       | 1 (1.49) | 66 (98.51) | 0.326 |
|                           | No    | 308            | 6 (1.95)         | 302 (98.05)      | 0.637       | 1 (1.49) | 307 (99.68) | 0.326 |
| Hemodialysis              | Yes   | 9              | 1 (11.11)        | 8 (88.89)        | 0.059       | 1 (11.11) | 8 (88.89) | 0.047 |
|                           | No    | 366            | 7 (1.91)         | 359 (98.09)      | 0.059       | 1 (11.11) | 357 (88.89) | 0.047 |
| Immunosuppressive therapy | Yes   | 13             | 1 (7.69)         | 12 (92.31)       | 0.248       | 0 (0.0)  | 13 (100.00) | 1.000 |
|                           | No    | 362            | 7 (1.93)         | 355 (98.07)      | 0.248       | 0 (0.0)  | 360 (99.45) | 1.000 |
renal disease (ESRD), the prevalence of HBV was 3.2% whereas, the prevalence of HCV was 7.4%.[39] Apparently, the lower prevalence rate of HBV in dialysis patients can be analyzed by the strong recommendation of universal HBV vaccination of hemodialysis patients. The high prevalence rate of HCV among dialysis patients in this study can be deduced by unavailability of HCV vaccine and inadequate infection control measures in the dialysis unit in Duhok. Furthermore, chronic HCV by itself may be a risk factor of ESRD requiring hemodialysis.[10,40]

Generally, in Duhok health care facilities a routine pre-blood transfusion and pre-surgical operation screening of HBV and HCV is compulsory, which averts these risk factors. Although routine pre-dental interventions are not obligatory in Duhok, dental procedures were not a significant risk factor in this study. However, in a previous study from Duhok, dental intervention was significantly associated with an increased risk of HBV infection among diabetic patients.[38]

Overall, this study can be used as an evidence base for primary care practice for testing HBsAg and anti-HCV in diabetic patients; and vaccinating those who are negative for HBV, to improve health outcomes among diabetic patients in Duhok health facilities.

There are a few limitations in this study. The duration of DM was not considered as it might increase the risk of acquiring HBV and HCV infections. The consumption of alcohol by diabetic patients may be biased due to socio-religious barrier in the society. Hence, the reported rate may be lower than the figure presented. HCV-RNA (RT-PCR) was not performed on positive anti-HCV patients so past infections were not excluded, if there were any.

In conclusion, although prevalence of HBV and HCV is higher among diabetic patients, its prevalence is low in comparison to other studies. It is recommended to screen HBsAg and anti-HCV in all alcoholic diabetic patients. Hemodialysis remains a significant risk factor for HCV transmission among diabetic patients with ESRD.

Further prospective case control studies with larger sample sizes including more risk factors are warranted to better understand the prevalence and associated factors with parenteral viral hepatitis among diabetic patients.

Acknowledgements

I would like to thank the staff of Shilan private laboratory for their kind help and assistance. Furthermore, I would like to extend my thanks to Dr. Idris Haji for his help with regards to diabetic patients. Finally, I would like to deeply thank my dear daughter Fatima M. Aghali for her outstanding support.

Declaration of patient consent

The author certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest

References

1. Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018;6:589-99.
2. World Health Organization. Global hepatitis report 2017. WHO; 2017.
3. Esmat G. Hepatitis C in the eastern Mediterranean region. 2013.
4. Tarky AM, Akram WA, Al-Naaimi AS, Omer AR. Epidemiology of viral hepatitis B and C in Iraq: A national survey 2005-2006. Zanco J Med Sci 2013;17:370-80.
5. Gutiérrez-Grobe Y, Ponciano-Rodríguez G, Méndez-Sánchez N. Viral hepatitis infection and insulin resistance: A review of the pathophysiological mechanisms. Salud Publica Mex 2011;53:S46-51.
6. Million Y, Teklu T, Alemu S, Ferede A, Belachew T, Desta K. Hepatitis B and hepatitis C viral infections and associated factors among patients with diabetes visiting gondar referral teaching hospital, Northwest Ethiopia: A comparative cross-sectional study. J Hepatocell Carcinoma 2019;6:143-50.
7. Tekin F, Gunsar F, Erdogan IL, Sertoz R, Karasu Z, Ersoz G, et al. Seroprevalence of hepatitis A, B, and C viruses in Turkish alcoholic cirrhotics and the impact of hepatitis B on clinical profile. J Infect Dev Ctries 2015;9:254-8.
8. Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: Prevalence and clinical spectrum. Scand J Gastroenterol 2003;38:864-70.
9. Galperim B, Cheinquer H, Stein A, Fonseca A, Lunge V, Ikuta N. Prevalence of hepatitis C virus in alcoholic patients: Role of parenteral risk factors. Arq Gastroenterol 2006;43:81-4.
10. Söderholm J, Millbourn C, Büscher K, Kövamees J, Schwarcz R, Lindahl K, et al. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. J Hepatol 2018;69:904-11.
11. Cadranel J-F, Di Martino V, Lambrey G, Mourlhon C, Nalet B, Aniaux M-L, et al. Prevalence of hepatitis C infection and risk factors in hospitalized diabetic patients: Results of a cross-sectional study. Gastroen Hepato 2008;20:829-36.
12. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: What we know in the new millennium. Am J Gastroenterol 2002;97:2714-24.
13. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: A follow-up study in Taiwan. Gastroenterology 2008;135:111-21.
14. Davila J, Morgan R, Shaib Y, McGlynn K, El-Serag H. Diabetes
increases the risk of hepatocellular carcinoma in the United States: A population based case control study. Gut 2005;54:533-9.

15. Fortress Diagnostic Limited. Unit 2c Antrim Technology Park, Antrim BT41 1QS (United Kingdom). 2007.

16. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 2017;40:S11-24.

17. Merza M, Hassan W, Muhammad A. Frequency of HBV and HCV among patients undergoing elective surgery in a tertiary care referral Hospital in Duhok, Iraqi Kurdistan. JMSCR 2014;2:1810-5.

18. Merza MA, Haji SM, Alsharafani AM, Muhammed SU. Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan: Are HBsAg and anti-HCV prerequisite screening parameters in tuberculosis control program? Int J Mycobacteriol 2016;5:313-7.

19. Ramadhan AA. Prevalence of hepatitis B and hepatitis C virus infections at premarital screening program in Duhok, Iraq. DMJ 2018;12:13-23.

20. Arrelas CCA, Rodrigues FB, Torquato MTdCG, Teixeira CRdS, Rodrigues FFL, Zanetti ML. Prevalence of serological markers for hepatitis and potential associated factors in patients with diabetes mellitus. Rev Lat Am Enfermagem 2018;26:e3085.

21. Gisi K, Cetinkaya A, Ozbek M, Kantarceken B, Gisi G, Koroglu S. Hepatitis B and C seroprevalence in patients with diabetes mellitus and its relationship with microvascular complications. Prz Gastroenterol 2017;12:105.

22. Hong YS, Chang Y, Ryu S, Cairezos-Achirica M, Kwon M-J, Zhang Y, et al. Hepatitis B and C virus infection and diabetes mellitus: A cohort study. Sci Rep 2017;7:4606.

23. Ndako JA, Echeonwu GO, Shidali NN, Bichi IA, Paul GA, Onovoh E, et al. Occurrence of Hepatitis C virus infection in type 2 diabetic patients attending Plateau state specialist hospital Jos Nigeria. Virol J 2009;6:98.

24. Jadoon NA, Shahzad MA, Yaqoob R, Hussain M, Ali N. Seroprevalence of hepatitis C in type 2 diabetes: Evidence for a positive association. Virol J 2010;7:304.

25. Villar LM, Gelenzez B, Vasques ACJ, Pires MLE, Miguel JC, da Silva EF, et al. Prevalence of hepatitis B and hepatitis C among diabetes mellitus type 2 individuals. PLoS one 2019;14:e021193.

26. Chen H-F, Li C-Y, Chen P, See T-T, Lee H-Y. Seroprevalence of hepatitis B and C in type 2 diabetic patients. J Chin Med Assoc 2006;69:146-52.

27. Bayramer HF, Erdem İ, Gündoğdu TT, Çınar Y, Barut Y, Demirtürk Ş. The prevalence of hepatitis b and hepatitis c virus in diabetic patients. Marmara Med J 2001;14:160-4.

28. Farshadpour F, Taherkhani R, Ravanbod MR, Eghbali SS. Prevalence and genotype distribution of hepatitis C virus infection among patients with type 2 diabetes mellitus. Med Princ Pract 2018;27:308-16.

29. Chen Y, Ji H, Shao J, Jia Y, Bao Q, Zhu J, et al. Different hepatitis C virus infection statuses show a significant risk of developing type 2 diabetes mellitus: A network meta-analysis. Dig Dis Sci 2019. doi: 10.1007/s10620-019-05918-7.

30. Schillie S, Xing J, Murphy T, Hu D. Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999–2010. J Viral Hepat 2012;19:674-6.

31. Ephraim R, Nisiah P, Asokunor D, Adoba P, Sakyi S, Anto E. Seroprevalence of hepatitis B and C viral infections among type 2 diabetics: A cross-sectional study in the Cape Coast Metropolis. Ann Med Health Sci Res 2014;4:719-22.

32. Shyu YC, Huang TS, Chien CH, Yeh CT, Lin CL, Chien RN. Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population-based cohort study. J Viral Hepat 2019;26:718-26.

33. Korkmaz H, Kesli R, Pamuk BO, Ipekci SH, Terzi Y, Kebapcilar L. Assessment of evidence for positive association and seroprevalence of hepatitis B and C in diabetic patients in a developing country. J Investig Med 2015;63:251-7.

34. Lu J, Hou X, Tu H, Tang Z, Xiang Y, Bao Y, et al. Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes. J Diabetes Investig 2017;8:619-25.

35. Serfaty L. Clinical implications of concomitant alcohol use, obesity, and viral hepatitis. Gastroenterology 2016;150:1718-22.

36. Amira CO, Lesi OA. Seroprevalence of hepatitis B and C infection among Nigerian subjects with chronic kidney disease. J Clin Sci 2017;14:58.

37. Cortes VF, Taveira A, Cruz HM, Reis AA, Cezar JS, Silva BS, et al. Prevalence of Hepatitis B and C virus infection among alcoholic individuals: Importance of screening and vaccination. Rev Inst Med Trop Sao Paulo 2017;59:e47.

38. Scherer M, Trens R, Harrell P, Mauro P, Latimer W. The role of drinking severity on sex risk behavior and HIV exposure among illicit drug users. Am J Addict 2013;22:239-45.

39. Ibrahim NM, Saleem ZSM, Hussein NR. The Prevalence of HIV, HCV, and HBV among hemodialysis patients attending Duhok Hemodialysis Center. Int J Infect 2018;5:e63246.

40. Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial 2019;32:108-18.